Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)

S
Sherif Farag, MD

Primary Investigator

Overview

The primary objective is to estimate and compare overall survival between the two arms:  patients who are Very Likely to find a MUD versus those who are Very Unlikely to find  a MUD.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplatic syndromes, Non-Hodgkin Lymphoma, Hodgkin's Lymphoma, Anaplastic Astrocytoma, Sickle Cell Disease
  • Age: - 100 Years
  • Gender: All

Inclusion Criteria

Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.

Any planned conditioning regimen and GVHD prophylaxis approach is eligible.

Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.

Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.

Updated on 20 Nov 2022. Study ID: 1904367480 (BMTCTN1702)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center